Androgens

"Androgens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.

Descriptor ID	D000728
MeSH Number(s)	D27.505.696.399.472.161
Concept/Terms	Androgens Androgens Androgenic Compounds Compounds, Androgenic Androgen Receptor Agonists Agonists, Androgen Receptor Receptor Agonists, Androgen Androgenic Agents Agents, Androgenic Androgen Effect Androgen Effect Effect, Androgen Androgen Effects Effects, Androgen

Below are MeSH descriptors whose meaning is more general than "Androgens".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Hormones, Hormone Substitutes, and Hormone Antagonists [D27.505.696.399]
Hormones [D27.505.696.399.472]
Androgens [D27.505.696.399.472.161]

Below are MeSH descriptors whose meaning is related to "Androgens".

Below are MeSH descriptors whose meaning is more specific than "Androgens".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Androgens" by people in this website by year, and whether "Androgens" was a major or minor topic of these publications.

Bar chart showing 53 publications over 21 distinct years, with a maximum of 6 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1999	0	1	1
2000	2	1	3
2006	1	0	1
2008	2	0	2
2009	0	2	2
2010	1	3	4
2011	1	2	3
2012	0	2	2
2013	2	2	4
2014	0	2	2
2015	0	2	2
2016	1	0	1
2017	1	3	4
2018	0	1	1
2019	3	0	3
2020	0	3	3
2021	0	2	2
2022	1	2	3
2023	0	6	6
2024	1	2	3

Below are the most recent publications written about "Androgens" by people in Profiles.

Chahdi A, Jorgez C, Seth A. Regulation of androgen receptor stability by the ?1 Pix/STUB1 complex. FASEB J. 2024 02; 38(2):e23408.

View in: PubMed
Colangelo LA, Carroll AJ, Perak AM, Gidding SS, Lima JAC, Lloyd-Jones DM. Association of 20-Year Longitudinal Depressive Symptoms With Left Ventricular Geometry Outcomes in the Coronary Artery Risk Development in Young Adults Study: A Role for Androgens? Psychosom Med. 2024 Feb-Mar 01; 86(2):60-71.

View in: PubMed
Richardson K, Sengupta M, Sujkowski A, Libohova K, Harris AC, Wessells R, Merry DE, Todi SV. A phenotypically robust model of spinal and bulbar muscular atrophy in Drosophila. J Neurosci Res. 2024 01; 102(1):e25278.

View in: PubMed
Morozov VM, Riva A, Sarwar S, Kim WJ, Li J, Zhou L, Licht JD, Daaka Y, Ishov AM. HIRA-mediated loading of histone variant H3.3 controls androgen-induced transcription by regulation of AR/BRD4 complex assembly at enhancers. Nucleic Acids Res. 2023 10 27; 51(19):10194-10217.

View in: PubMed
Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol. 2024 Mar; 20(9):493-505.

View in: PubMed
Gomaa S, Kelly WK, Mitchell E, Storozynsky E, Zeigler-Johnson C, Juon HS, Wen KY. Racial disparities in new-onset diabetes mellitus in prostate cancer patients on androgen deprivation therapy: a retrospective analysis of TriNetX data. World J Urol. 2023 Sep; 41(9):2351-2357.

View in: PubMed
Armstrong AJ, Iguchi T, Azad AA, Villers A, Alekseev B, Petrylak DP, Szmulewitz RZ, Alcaraz A, Shore ND, Holzbeierlein J, Gomez-Veiga F, Rosbrook B, Zohren F, Haas GP, Gourgiotti G, El-Chaar N, Stenzl A. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. Eur Urol. 2023 08; 84(2):229-241.

View in: PubMed
Masud N, Aldahish A, Iczkowski KA, Kale A, Shah GV. Zinc finger protein-like 1 is a novel neuroendocrine biomarker for prostate cancer. Int J Oncol. 2023 Mar; 62(3).

View in: PubMed
Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, Shore N, Kopyltsov E, Kalebasty AR, B?gemann M, Ye D, Cruz F, Suzuki H, Kapur S, Srinivasan S, Verholen F, Kuss I, Joensuu H, Smith MR. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. J Clin Oncol. 2023 07 10; 41(20):3595-3607.

View in: PubMed
Seth A, Rivera A, Chahdi A, Choi IS, Medina-Martinez O, Lewis S, O'Neill M, Ridgeway A, Moore J, Jorgez C, Lamb DJ. Gene dosage changes in KCTD13 result in penile and testicular anomalies via diminished androgen receptor function. FASEB J. 2022 11; 36(11):e22567.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement